Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JW (Cayman) Therapeutics CoJWCTF -4.38%26 Equity-to-Asset is 0.56 as of Dec. 2025, which is 24% below its 10-year median of 0.74. GuruFocus rates JWCTF with a GF Score™ of 26/100 and a GF Value™ of $0.59 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,414 Biotechnology companies, JW (Cayman) Therapeutics Co ranks worse than 63.58% on this metric.
JW (Cayman) Therapeutics Co (OTCPK:JWCTF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
JW (Cayman) Therapeutics Co Equity-to-Asset Related Terms
JW (Cayman) Therapeutics Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JWCTF vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JW (Cayman) Therapeutics Co Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where JW (Cayman) Therapeutics Co's Equity-to-Asset falls into.
JW (Cayman) Therapeutics Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
JW (Cayman) Therapeutics Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JW (Cayman) Therapeutics Co (JWCTF) has a Equity-to-Asset of 0.56 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on JW (Cayman) Therapeutics Co and its competitors. This is 24% below median its historical median of 0.74. According to the industry distribution chart, JW (Cayman) Therapeutics Co ranks #899 out of 1414 companies in the Biotechnology industry, placing it in the top 63.6%.
Is JW (Cayman) Therapeutics Co's Equity-to-Asset too high?
JW (Cayman) Therapeutics Co's current Equity-to-Asset of 0.56 is 24% below median its 10-year median of 0.74. The Biotechnology industry median Equity-to-Asset is 0.68. JW (Cayman) Therapeutics Co's value of 0.56 is 17.6% below this industry median. Based on the distribution chart, JW (Cayman) Therapeutics Co ranks #899 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, JW (Cayman) Therapeutics Co ranks #899 out of 1414 companies for Equity-to-Asset. This places JW (Cayman) Therapeutics Co in the lower half of its industry. The industry median Equity-to-Asset is 0.68. JW (Cayman) Therapeutics Co's value of 0.56 is 17.6% below this benchmark. While the company's 10-year median is 0.74 vs. the industry median of 0.68, JW (Cayman) Therapeutics Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JW (Cayman) Therapeutics Co's current Equity-to-Asset of 0.56 is 17.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on JW (Cayman) Therapeutics Co and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JW (Cayman) Therapeutics Co's current Equity-to-Asset is 0.56, which is 24% below median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.59, compared to a current price of $0.20 — trading 65.7% below its estimated fair value. The current Equity-to-Asset is 0.56, which is 24% below median its 10-year median of 0.74 and 17.6% below the Biotechnology industry median of 0.68. JW (Cayman) Therapeutics Co's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current Equity-to-Asset is 0.56 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued.
The current stock price of $0.20 is trading 65.7% below its estimated GF Value™ of $0.59.
GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.
Key valuation signals for JWCTF:
Equity-to-Asset: 0.56 (24% below median its 10-year median of 0.74)
GF Value™: $0.59 vs. price of $0.20 (65.7% below fair value)
Industry Position: 17.6% below the Biotechnology median (#899 of 1414)
No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
26GF Score
Get the complete analysis for JWCTF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JWCTF has been successfully added to your 
